Epigenetic Modifications and Non-Coding RNA in Diabetes-Mellitus-Induced Coronary Artery Disease: Pathophysiological Link and New Therapeutic Frontiers
FR Prandi, D Lecis, F Illuminato, M Milite… - International Journal of …, 2022 - mdpi.com
Diabetes mellitus (DM) is a glucose metabolism disorder characterized by chronic
hyperglycemia resulting from a deficit of insulin production and/or action. DM affects more …
hyperglycemia resulting from a deficit of insulin production and/or action. DM affects more …
Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review
L Karkhaneh, O Tabatabaei-Malazy… - Journal of Diabetes & …, 2022 - Springer
Purpose Genetic factors have a role in response to a target medication (personalized
medicine). This study aimed to review available evidence about the relationship between …
medicine). This study aimed to review available evidence about the relationship between …
The revolution of pharmaco-omics: ready to open new avenues in materializing precision medicine?
G Ragia, VG Manolopoulos - Pharmacogenomics, 2022 - Taylor & Francis
Full article: The Revolution of Pharmaco-Omics: Ready to Open new Avenues in
Materializing Precision Medicine? Skip to Main Content Taylor and Francis Online …
Materializing Precision Medicine? Skip to Main Content Taylor and Francis Online …
SLCO1B1 c.521T>C gene polymorphism decreases hypoglycemia risk in sulfonylurea-treated type 2 diabetic patients
G Ragia, N Atzemian, A Maslarinou… - Drug Metabolism and …, 2022 - degruyter.com
Objectives Pharmacogenomics can explain some of the heterogeneity of sulfonylurea (SU)-
related hypoglycemia risk. Recently, a role of OATP1B1, encoded by SLCO1B1 gene, on SU …
related hypoglycemia risk. Recently, a role of OATP1B1, encoded by SLCO1B1 gene, on SU …